.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Healthtrust
Citi
Cantor Fitzgerald
Covington
Queensland Health
McKesson
Federal Trade Commission
Teva
Fish and Richardson

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,414,016

« Back to Dashboard

Which drugs does patent 6,414,016 protect, and when does it expire?


Patent 6,414,016 protects AMITIZA and is included in one NDA. There has been one Paragraph IV challenge on Amitiza.

This patent has thirty-seven patent family members in twenty-four countries.

Summary for Patent: 6,414,016

Title: Anti-constipation composition
Abstract:An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): ##STR1## where X.sub.1 and X.sub.2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.
Inventor(s): Ueno; Ryuji (Potomac, MD)
Assignee: Sucampo, A.G. (Zurich, GH)
Application Number:09/655,760
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Sucampo Pharma LlcAMITIZAlubiprostoneCAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► Subscribe► SubscribeMETHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
Sucampo Pharma LlcAMITIZAlubiprostoneCAPSULE;ORAL021908-001Jan 31, 2006RXYesYes► Subscribe► Subscribe► SubscribeMETHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
Sucampo Pharma LlcAMITIZAlubiprostoneCAPSULE;ORAL021908-001Jan 31, 2006RXYesYes► Subscribe► Subscribe► SubscribeMETHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,414,016

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,610,732 Anti-constipation composition► Subscribe
8,748,454Anti-constipation composition► Subscribe
8,114,890Anti-constipation composition► Subscribe
8,071,613Anti-constipation composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,414,016

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI305147► Subscribe
Russian Federation2278666► Subscribe
Portugal1857105► Subscribe
Portugal1315485► Subscribe
New Zealand524401► Subscribe
Norway332701► Subscribe
Norway20030996► Subscribe
Netherlands300757► Subscribe
MexicoPA03001959► Subscribe
South Korea100918223► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Covington
Fish and Richardson
Federal Trade Commission
Boehringer Ingelheim
Medtronic
UBS
Chubb
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot